日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study

利用局部和系统免疫特征分析来区分广泛期小细胞肺癌患者对一线信迪利单抗(抗PD-1抗体)联合化疗的不同反应:一项II期研究的探索性生物标志物分析

Xie, Mengqing; Bao, Minwei; Dong, Xiaorong; Wu, Lin; Liu, Li; Zhao, Jing; Chu, Xiangling; Wu, Yan; Ji, Xianxiu; Fang, Yujia; Yu, Xin; Zhang, Shiji; Wang, Qi; Hu, Tao; Wang, Jin; Zhu, Changbin; Su, Chunxia

PMS2 amplification contributes brain metastasis from lung cancer.

PMS2 扩增是肺癌脑转移的促成因素

Chen Jianing, Hu Congli, Yang Hainan, Wang Li, Chu Xiangling, Yu Xin, Zhang Shiji, Li Xuefei, Zhao Chao, Cheng Lei, Hong Weiping, Liu Da, Wen Lei, Su Chunxia

Identification of nomogram associated with durable clinical benefit gene for advanced non-small cell lung cancer with sensitivity to responsive to immunotherapy

识别与晚期非小细胞肺癌持久临床获益基因相关的列线图,该癌症对免疫疗法敏感

Wang, Li; Chu, Xiangling; Yu, Xin; Su, Chunxia

A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

一项关于HER2突变晚期肺腺癌一线治疗及后续吡咯替尼治疗的回顾性研究

Wang, Li; Wu, Yueran; Ren, Zhixuan; Chu, Xiangling; Chen, Jianing; Liu, Li; Zhao, Jing; Yu, Xin; Xie, Mengqing; Su, Chunxia

Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistance

利用全谱流式细胞术对外周血单核细胞(PBMC)进行全面分析,以评估其作为EGFR-TKI耐药性非小细胞肺癌(NSCLC)免疫治疗生物标志物的潜力。

Zhou, Juan; Chu, Xiangling; Zhao, Jing; Xie, Mengqing; Wu, Jing; Yu, Xin; Fang, Yujia; Li, Yazhou; Li, Xiyan; Su, Chunxia

Indoor air pollution: An important risk factor for lung cancer among Asian women without a history of smoking

室内空气污染:亚洲无吸烟史女性罹患肺癌的重要危险因素

Chu, Xiangling; Wang, Qi; Su, Chunxia

Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study

免疫检查点抑制剂治疗HER2突变型肺腺癌的疗效:一项多中心回顾性研究

Chu, Xiangling; Qiang, Huiping; Xie, Mengqing; Li, Xing; Zhao, Jing; Wu, Yan; Zhou, Juan; Ye, Jinyan; Zhao, Chao; Han, Chaonan; Chu, Tianqing; Su, Chunxia

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors

接受 PD-1/PD-L1 抑制剂治疗的非小细胞肺癌患者中与高血压相关的肺部不良事件

Chen, Jianing; Wen, Yaokai; Chu, Xiangling; Liu, Yuzhi; Su, Chunxia

Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer

基线血浆PCSK9水平低与晚期非小细胞肺癌免疫检查点抑制剂的良好临床疗效相关

Xie, Mengqing; Yu, Xin; Chu, Xiangling; Xie, Huikang; Zhou, Juan; Zhao, Jing; Su, Chunxia

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

免疫治疗进展后,基于检查点抑制剂的联合疗法在晚期非小细胞肺癌中取得了良好的临床疗效

Yu, Xin; Chu, Xiangling; Wu, Yan; Zhou, Juan; Zhao, Jing; Zhou, Fei; Han, Chaonan; Su, Chunxia